Group items tagged Pharmaceutical - medindia

ACETO completes acquisition of PACK Pharmaceuticals - 1 views

otc.pharmaceutical-business-review.com/...pharmaceuticals-010514-4256158

health news medical pharma

shared by Alex Parker on 01 May 14 - No Cached

Alex Parker on 01 May 14

Published 01 May 2014 ACETO has announced that its wholly-owned subsidiary, Rising Pharmaceutical, has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100m.

<div class="cArrow"> </div><div class="cContentInner">Published 01 May 2014 ACETO has announced that its wholly-owned subsidiary, Rising Pharmaceutical, has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100m.</div>

...

Cancel

Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals - 1 views

otc.pharmaceutical-business-review.com/...pharmaceuticals-200314-4200767

health news medical pharma

shared by Alex Parker on 24 Mar 14 - No Cached

Alex Parker on 24 Mar 14

PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 20 March 2014 Ireland-based specialty pharmaceutical firm Actavis has entered into an agreement with Noven Pharmaceuticals to settle all outstanding patent litigation related to its generic version of Daytrana (Methylphenidate Transdermal System). Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.</div>

...

Cancel

Novartis announces acquisition of CoStim Pharmaceuticals - 0 views

processandproduction.pharmaceutical-business-review.com/...pharmaceuticals-180214-4179543

health news pharma

shared by Alex Parker on 19 Feb 14 - No Cached

Alex Parker on 19 Feb 14

Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

<div class="cArrow"> </div><div class="cContentInner">Novartis has acquired CoStim Pharmaceuticals, an immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.</div>

...

Cancel

RainTree launches new cloud-based analytics portal for pharmaceutical industry - 1 views

itsoftware.pharmaceutical-business-review.com/...utical-industry-160414-4215651

health news medical pharma

shared by Alex Parker on 17 Apr 14 - No Cached

Alex Parker on 17 Apr 14

RainTree Oncology Services and Information Builders have launched OncoExplorer, a new cloud-based analytics portal that offers unprecedented decision-support capabilities to pharmaceutical companies.

<div class="cArrow"> </div><div class="cContentInner">RainTree Oncology Services and Information Builders have launched OncoExplorer, a new cloud-based analytics portal that offers unprecedented decision-support capabilities to pharmaceutical companies.</div>

...

Cancel

Oramed gets third Australia patent for oral Exenatide - 1 views

processandproduction.pharmaceutical-business-review.com/...-oral-exenatide-120314-4194691

health news medical pharma

shared by Alex Parker on 13 Mar 14 - No Cached

Alex Parker on 13 Mar 14

Israel-based clinical-stage pharmaceutical firm Oramed Pharmaceuticals has received its third patent in Australia for oral administration of exenatide from the Australian government's patent office 'IP Australia'.

<div class="cArrow"> </div><div class="cContentInner">Israel-based clinical-stage pharmaceutical firm Oramed Pharmaceuticals has received its third patent in Australia for oral administration of exenatide from the Australian government's patent office 'IP Australia'.</div>

...

Cancel

How a pharmaceutical market researcher is frustrated? - 0 views

whybenchmarking.com/...armaceutical-market-researcher

pharmaceutical market researcher medical frustrated best practices

shared by Hellan George on 28 Aug 15 - No Cached

Hellan George on 28 Aug 15

Not that long ago, I was updating a key research project here at Best Practices; and as usual, I was waiting on approval from our research manager...

<div class="cArrow"> </div><div class="cContentInner">Not that long ago, I was updating a key research project here at Best Practices; and as usual, I was waiting on approval from our research manager...</div>

...

Cancel

Chindex to be acquired by TPG and Fosun Pharma - 0 views

processandproduction.pharmaceutical-business-review.com/...nd-fosun-pharma-180214-4179302

health medical news pharma

shared by Alex Parker on 19 Feb 14 - No Cached

Alex Parker on 19 Feb 14

Chindex International has entered into a definitive merger agreement with a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group)

<div class="cArrow"> </div><div class="cContentInner">Chindex International has entered into a definitive merger agreement with a buyer consortium of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group)</div>

...

Cancel

Vertex gets FDA approval for Kalydeco sNDA - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...r-kalydeco-snda-240214-4182411

health medical news pharma day

shared by Alex Parker on 24 Feb 14 - No Cached

Alex Parker on 24 Feb 14

PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).</div>

...

Cancel

Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...reat-friedreichs-ataxia-180314

health news medical pharma daily

shared by Alex Parker on 18 Mar 14 - No Cached

Alex Parker on 18 Mar 14

US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.

<div class="cArrow"> </div><div class="cContentInner">US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.</div>

...

Cancel

Teva launches generic Xeloda tablets in US - 1 views

processandproduction.pharmaceutical-business-review.com/...a-tablets-in-us-100314-4192411

health news pharma daily

shared by Alex Parker on 11 Mar 14 - No Cached

Alex Parker on 11 Mar 14

Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda tablets, 150mg and 500mg, in the US.

<div class="cArrow"> </div><div class="cContentInner">Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda tablets, 150mg and 500mg, in the US.</div>

...

Cancel

Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...vt-pe-treatment-090414-4211375

health news medical pharma

shared by Alex Parker on 09 Apr 14 - No Cached

Alex Parker on 09 Apr 14

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).

<div class="cArrow"> </div><div class="cContentInner">Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).</div>

...

Cancel

Tetraphase's eravacycline gets FDA fast track status - 1 views

regulatoryaffairs.pharmaceutical-business-review.com/...st-track-status-030414-4208894

health news medical pharma

shared by Alex Parker on 04 Apr 14 - No Cached

Alex Parker on 04 Apr 14

The US Food & Drug Administration (FDA) has granted fast track designations for both the intravenous (IV) and oral formulations of Tetraphase Pharmaceuticals' lead antibiotic candidate, eravacycline.

<div class="cArrow"> </div><div class="cContentInner">The US Food & Drug Administration (FDA) has granted fast track designations for both the intravenous (IV) and oral formulations of Tetraphase Pharmaceuticals' lead antibiotic candidate, eravacycline.</div>

...

Cancel

Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn - 1 views

manufacturing.pharmaceutical-business-review.com/...lergan-for-45bn-230414-4218796

health news medical pharma

shared by Alex Parker on 23 Apr 14 - No Cached

Alex Parker on 23 Apr 14

PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 23 April 2014 Canada-based Valeant Pharmaceuticals (Valeant) and activist investor Bill Ackman have revealed details of their offer to acquire Botox-maker Allergan, in a cash-and-stock deal that could be worth more than $45bn. Under the deal, Allergan investors would receive $48.30 in cash and 0.83 of a Valeant stock for each share they own.</div>

...

Cancel

Novartis reshapes business by signing deals with GSK, Eli Lilly - 2 views

manufacturing.pharmaceutical-business-review.com/...h-gsk-eli-lilly-220414-4218360

health news medical pharma daily

shared by Alex Parker on 23 Apr 14 - No Cached

Alex Parker on 23 Apr 14

PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.

<div class="cArrow"> </div><div class="cContentInner">PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.</div>

...

Cancel

Epic Sciences partners with LabCorp for circulating tumor cell technology - 0 views

itsoftware.pharmaceutical-business-review.com/...cell-technology-300114-4168451

health medical news pharma

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

<div class="cArrow"> </div><div class="cContentInner">Epic Sciences has announced an agreement with Laboratory Corporation of America Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.</div>

...

Cancel

OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...manage-gep-nets-300114-4168590

health medical news

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors

<div class="cArrow"> </div><div class="cContentInner">Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors</div>

...

Cancel

Immuneering expands relationship with Bristol-Myers Squibb - 0 views

itsoftware.pharmaceutical-business-review.com/...ol-myers-squibb-300114-4168880

health medical news pharma

shared by Alex Parker on 31 Jan 14 - No Cached

Alex Parker on 31 Jan 14

Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.

<div class="cArrow"> </div><div class="cContentInner">Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.</div>

...

Cancel

BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views

laboratoryinstrumentation.pharmaceutical-business-review.com/...iagnostic-assay-110214-4175302

news medical health pharma

shared by Alex Parker on 11 Feb 14 - No Cached

Alex Parker on 11 Feb 14

BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.

<div class="cArrow"> </div><div class="cContentInner">BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.</div>

...

Cancel

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

regulatoryaffairs.pharmaceutical-business-review.com/...roved-in-canada-140214-4177946

health medical news pharma

shared by Alex Parker on 17 Feb 14 - No Cached

Alex Parker on 17 Feb 14

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.

<div class="cArrow"> </div><div class="cContentInner">Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.</div>

...

Cancel

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

processandproduction.pharmaceutical-business-review.com/...ide-based-drugs-060214-4172952

health medical news pharma

shared by Alex Parker on 06 Feb 14 - No Cached

Alex Parker on 06 Feb 14

Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology

<div class="cArrow"> </div><div class="cContentInner">Aegis Therapeutics has been awarded its first patent for oral delivery of nucleotide analog based drugs based upon the company's patented Intravail transmucosal absorption enhancer technology</div>

...

Cancel

Group items tagged

ACETO completes acquisition of PACK Pharmaceuticals - 1 views

Actavis to settle patent litigation of Daytrana with Noven Pharmaceuticals - 1 views

Novartis announces acquisition of CoStim Pharmaceuticals - 0 views

RainTree launches new cloud-based analytics portal for pharmaceutical industry - 1 views

Oramed gets third Australia patent for oral Exenatide - 1 views

How a pharmaceutical market researcher is frustrated? - 0 views

Chindex to be acquired by TPG and Fosun Pharma - 0 views

Vertex gets FDA approval for Kalydeco sNDA - 0 views

Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views

Teva launches generic Xeloda tablets in US - 1 views

Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views

Tetraphase's eravacycline gets FDA fast track status - 1 views

Valeant, Ackman sign deal to acquire Botox-maker Allergan for $45bn - 1 views

Novartis reshapes business by signing deals with GSK, Eli Lilly - 2 views

Epic Sciences partners with LabCorp for circulating tumor cell technology - 0 views

OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views

Immuneering expands relationship with Bristol-Myers Squibb - 0 views

BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views

Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views

Aegis awarded its first patent for oral delivery of nucleotide-based drugs - 0 views

Related searches